Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.

This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

A large retrospective multicenter study demonstrated the feasibility and efficacy of a short duration of talquetamab bridging therapy before B-cell maturation antigen (BCMA)-targeted chimeric ...

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

In the Mithic-FL1 trial, patients with newly diagnosed high-burden follicular lymphoma (FL) demonstrated complete response (CR) rates of 80% and manageable adverse events with outpatient ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...